fda approvals in gvhd, crc, and aml, a priority review in mcl, and more
Published 7 years ago • 115 plays • Length 8:45Download video MP4
Download video MP3
Similar videos
-
9:25
fda approvals in large b-cell lymphoma and melanoma, priority reviews in cscc and nsclc, and more
-
7:39
fda approvals in all, ovarian cancer, priority review in ctcl, and snda submitted in rcc
-
10:55
fda approvals in cinv and her2 breast cancer, priority review in myelofibrosis, and more
-
12:17
odac support for 5 agents, nda in melanoma, breakthrough designation in gvhd, and more
-
2:22
determining how to optimally use fda-approved drugs in chronic gvhd
-
4:26
fda approvals in 2015: year in review
-
7:05
fda approval of crysvita® for x-linked hypophosphatemia (xlh)
-
1:58
fda review and approval process for biosimilar medications
-
0:30
fda qsr compliance for medical device manufacturers | fda consultant | gmp
-
7:22
what is new for treating acute gvhd?
-
2:12
fda approves generic epipen
-
0:26
fda clears generic rival to high-priced epipen
-
18:50
how can we deal with the explosion of new treatments? - fda
-
1:02
rachel zabaneh, md, faap
-
2:14
dr ehrenstorfer spotlight on: pfas
-
17:35
regulatory matters, us‐view
-
3:13
gvhd prophylaxis: ptcy vs atg in aml with allo-hsct
-
2:16
fda considerations for approval of therapies in gi cancers
-
48:14
"what fda approval means: the limitations of pre-market studies"